Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 20, 2017. The report discloses changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) resulting from the vesting of pre-tax awards granted in 2014 under the GlaxoSmithKline Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific equity transactions related to executive compensation.
| Transaction Type | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| Tax Withholding | ADSs (US37733W1053) | $40.57 | 12,486 |
Breakdown by Executive:
- Dr. M M Slaoui (Chairman, Global Vaccines): 12,486 ADSs withheld (9,237 Deferred, 3,249 Matching).
- Mr. D E Troy (SVP & General Counsel): 4,488 ADSs withheld (3,280 Deferred, 1,208 Matching).
Material Changes
The filing reports a reduction in the shareholdings of the named executives due to the mandatory withholding of shares to satisfy tax liabilities associated with the vesting of 2014 awards. No other material changes to the company's financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a routine regulatory notification of insider transactions.
Key Facts for Investor Verification
- Verify the total number of ADSs withheld for tax purposes (12,486) against the company's broader insider trading reports.
- Confirm the transaction date of February 16, 2017, and the execution price of $40.57 per ADS.
- Note that this filing does not reflect the company's operational performance or financial results for the period.